Indeed, in the CheckMate 057 (Checkpoint Pathway and Nivolumab Clinical Trial Evaluation 057) trial, a subgroup of patients with NSCLC harboring KRAS mutations experienced greater benefit from the anti-ePD-1 checkpoint inhibitor nivolumab [21,22,23,24,25,26]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.